Global Leading Market Research Publisher QYResearch announces the release of its latest report *“Endovascular Aneurysm Repair – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”*. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Endovascular Aneurysm Repair market, including market size, share, demand, industry development status, and forecasts for the next few years.
For vascular surgeons, interventional radiologists, and healthcare systems managing patients with aortic aneurysms, the traditional approach—open surgical repair—has long been associated with significant morbidity, extended hospital stays, and substantial recovery periods. Aortic aneurysms, if left untreated, carry the risk of rupture with high mortality rates, yet many patients, particularly the elderly or those with comorbidities, are poor candidates for open surgery. Endovascular aneurysm repair (EVAR) addresses this clinical challenge through a minimally invasive approach. Using catheter-based techniques, physicians deploy a stent-graft through the femoral artery, navigating it to the site of the aneurysm, where it is expanded to exclude the aneurysm sac from circulation. This approach eliminates the need for open abdominal or thoracic incisions, reducing perioperative complications, shortening hospital stays, and expanding treatment options to patients previously considered inoperable.
The global market for Endovascular Aneurysm Repair was estimated to be worth US$ 576 million in 2024 and is forecast to a readjusted size of US$ 925 million by 2031, advancing at a CAGR of 7.1% during the forecast period 2025-2031.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/3670572/endovascular-aneurysm-repair
Clinical Indications and Procedural Evolution
Endovascular aneurysm repair is indicated for two primary anatomical locations:
Abdominal aortic aneurysm (AAA) represents the largest application segment, with EVAR established as the first-line treatment for anatomically suitable patients. The procedure has demonstrated equivalent or superior outcomes compared to open repair in multiple randomized controlled trials, with lower perioperative mortality and faster recovery times.
Thoracic aortic aneurysm (TAA) represents a smaller but growing segment, with thoracic endovascular aortic repair (TEVAR) offering similar advantages for patients with aneurysms in the descending thoracic aorta. The complexity of thoracic anatomy, including branch vessels supplying the spinal cord and viscera, has driven innovation in fenestrated and branched devices.
Exclusive Industry Insight: The Shift Toward Fenestrated and Physician-Modified Devices
A distinctive observation from our analysis is the evolution of EVAR technology to address increasingly complex anatomy. While standard EVAR devices are suitable for patients with adequate proximal and distal sealing zones (aneurysm necks), a significant proportion of patients present with anatomy that precludes standard repair—short necks, angulated necks, or involvement of branch vessels.
Fenestrated EVAR (FEVAR) addresses these challenges through custom-manufactured devices with openings (fenestrations) that preserve flow to renal and mesenteric arteries. These devices expand the treatable patient population but require extended manufacturing lead times (typically 4–8 weeks), limiting utility for symptomatic or ruptured aneurysms.
Physician-modified endografts have emerged as an alternative for urgent cases, where surgeons modify standard devices in the operating room to accommodate patient-specific anatomy. While offering immediate availability, this approach raises regulatory, quality control, and reproducibility concerns.
Chimney and snorkel techniques provide another approach to preserving branch vessel flow, using parallel grafts alongside the main endograft. These techniques expand treatment options for complex anatomy but are associated with increased risk of gutter endoleaks (persistent blood flow outside the graft) compared to fenestrated devices.
Market Drivers: Aging Population and Minimally Invasive Trends
The EVAR market is propelled by several enduring demographic and technological trends:
Aging populations in developed economies increase the prevalence of aortic aneurysms, which are predominantly diseases of older adults. Screening programs (such as the UK’s NHS AAA Screening Programme) have increased early detection, driving demand for elective repair.
Minimally invasive procedure preferences align with broader healthcare trends favoring shorter hospital stays, reduced postoperative pain, and faster return to normal activity. EVAR’s ability to achieve these outcomes has made it the preferred approach for anatomically suitable patients.
Expanding indications through device innovation are progressively treating more complex anatomy, capturing patients previously managed with open surgery or surveillance. Fenestrated, branched, and physician-modified devices represent the frontier of this expansion.
Recent Industry Developments and Market Dynamics (Q4 2024 – Q1 2026)
The past eighteen months have witnessed continued innovation and strategic positioning across the EVAR landscape:
- Medtronic expanding its endovascular portfolio with next-generation fenestrated devices and continued development of its Valiant thoracic stent-graft platform, emphasizing durability and ease of deployment.
- W. L. Gore & Associates advancing its Excluder and TAG device lines with innovations in low-profile delivery systems, enabling percutaneous access through smaller arteriotomies.
- Cook Medical maintaining its position in the fenestrated and branched device segment, with continued emphasis on custom-manufactured solutions for complex aortic pathology.
- Terumo Medical Corporation expanding its vascular access portfolio to complement EVAR procedures, including introducer sheaths and guidewires optimized for complex endovascular cases.
- Endologix focusing on its Alto abdominal stent-graft platform, designed to address limitations of previous-generation devices in challenging anatomy.
Technology Deep Dive: Device Design and Procedural Considerations
EVAR device design encompasses several critical parameters:
Stent-graft materials typically combine nitinol (nickel-titanium) self-expanding stents with polytetrafluoroethylene (PTFE) or polyester graft fabric. Nitinol provides the flexibility to accommodate aortic curvature while maintaining radial force to achieve seal.
Delivery system profile determines the required arteriotomy size and patient eligibility for percutaneous versus surgical access. Low-profile systems (as small as 14–16 French) enable percutaneous closure without open femoral cutdown, reducing procedural morbidity.
Fixation mechanisms include proximal fixation hooks or barbs that engage the aortic wall, along with radial force to maintain seal. Suprarenal fixation (hooks positioned above the renal arteries) provides additional stability but introduces risk of renal artery compromise.
Endoleak management remains a key clinical consideration. Endoleaks—persistent blood flow within the aneurysm sac—can occur from incomplete seal at the proximal or distal landing zones, branch vessel backfilling, or device fabric porosity. Surveillance imaging (typically computed tomography angiography) is required post-procedure to identify endoleaks requiring reintervention.
Market Challenges and Risk Considerations
The EVAR market faces several ongoing challenges:
Long-term durability concerns have prompted continued surveillance requirements and, in some cases, secondary interventions. Device migration, endoleak, and graft material fatigue necessitate life-long follow-up, adding to healthcare system costs.
Anatomic suitability limits EVAR applicability. Patients with short or angulated aneurysm necks, extensive thrombus, or involvement of visceral branches may not be candidates for standard devices, requiring fenestrated or branched solutions with associated complexity and cost.
Regulatory pathways for endovascular devices require extensive clinical evidence supporting safety and durability. Fenestrated and branched devices face additional regulatory scrutiny given their complexity and the critical anatomy involved.
Market Segmentation
By procedure type, the market is segmented into percutaneous EVAR, fenestrated EVAR, aortic stents & TAA grafts, and others. Percutaneous EVAR represents the largest segment for standard anatomy, while fenestrated EVAR and TAA grafts are growing faster as device technology expands treatable anatomy.
By application, the market is segmented into abdominal aortic aneurysm (AAA) and thoracic aortic aneurysm (TAA) , with AAA representing the larger segment due to higher prevalence and longer history of EVAR adoption.
Competitive Landscape
Key players operating in the Endovascular Aneurysm Repair market include: Abbott Laboratories, BD, Cardinal Health, Cook Medical, Endologix, Lombard Medical, Medtronic, Koninklijke Philips N.V., Terumo Medical Corporation, and W. L. Gore & Associates. These companies compete on device durability, ease of deployment, anatomic range of treatment, and clinical evidence supporting their products in a market where patient safety and procedural outcomes are paramount.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
